Article in Viruses, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
5 citing papers in PubMed, 10 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
22 authors at 10 institutions in 1 country.
Carlos LouceraBioinformatics Area, Andalusian Public Foundation Progress and Health-FPS, 41013 Sevilla, Spain.ORCID 0000-0001-9598-6965
Javier Perez-FloridoBioinformatics Area, Andalusian Public Foundation Progress and Health-FPS, 41013 Sevilla, Spain.
Carlos S Casimiro-SoriguerBioinformatics Area, Andalusian Public Foundation Progress and Health-FPS, 41013 Sevilla, Spain.
Francisco M OrtuñoBioinformatics Area, Andalusian Public Foundation Progress and Health-FPS, 41013 Sevilla, Spain.
Rosario CarmonaBioinformatics Area, Andalusian Public Foundation Progress and Health-FPS, 41013 Sevilla, Spain.ORCID 0000-0002-4235-2886
Gerrit BostelmannBioinformatics Area, Andalusian Public Foundation Progress and Health-FPS, 41013 Sevilla, Spain.ORCID 0000-0002-1690-6347
L Javier Martínez-GonzálezGENYO, Centre for Genomics and Oncological Research, Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, 18016 Granada, Spain.ORCID 0000-0003-2202-0662
Dolores Muñoyerro-MuñizSubdirección Técnica Asesora de Gestión de la Información, Servicio Andaluz de Salud, 41001 Sevilla, Spain.
Román VillegasSubdirección Técnica Asesora de Gestión de la Información, Servicio Andaluz de Salud, 41001 Sevilla, Spain.
Jesus Rodriguez-BañoInstitute of Biomedicine of Seville, IBiS, University Hospital Virgen del Rocío/CSIC/University of Seville, 41013 Sevilla, Spain.ORCID 0000-0001-6732-9001
Manuel Romero-GomezInstitute of Biomedicine of Seville, IBiS, University Hospital Virgen del Rocío/CSIC/University of Seville, 41013 Sevilla, Spain.ORCID 0000-0001-8494-8947
Nicola LorussoDirección General de Salud Pública, Consejería de Salud y Familias, Junta de Andalucía, 41020 Sevilla, Spain.
Javier Garcia-LeónDepartamento de Metafísica y Corrientes Actuales de la Filosofía, Ética y Filosofía Política, Universidad de Sevilla, 41004 Sevilla, Spain.ORCID 0000-0003-3460-8818
Jose M Navarro-MaríServicio de Microbiología, Hospital Virgen de las Nieves, 18014 Granada, Spain.ORCID 0000-0002-5227-5167
Pedro Camacho-MartinezServicio de Microbiología, Unidad Clínica Enfermedades Infecciosas, Microbiología y Medicina Preventiva, Hospital Universitario Virgen del Rocío, 41013 Sevilla, Spain.
Laura Merino-DiazServicio de Microbiología, Unidad Clínica Enfermedades Infecciosas, Microbiología y Medicina Preventiva, Hospital Universitario Virgen del Rocío, 41013 Sevilla, Spain.
Adolfo de SalazarCentro de Investigación Biomédica en Red en Enfermedades Infecciosas (CIBERINFEC), ISCIII, 28029 Madrid, Spain.ORCID 0000-0002-4318-858X
Laura ViñuelaCentro de Investigación Biomédica en Red en Enfermedades Infecciosas (CIBERINFEC), ISCIII, 28029 Madrid, Spain.ORCID 0000-0003-1157-4299
The Andalusian Covid-Sequencing Initiative
Jose A LepeInstitute of Biomedicine of Seville, IBiS, University Hospital Virgen del Rocío/CSIC/University of Seville, 41013 Sevilla, Spain.ORCID 0000-0002-3635-4930
Federico GarciaCentro de Investigación Biomédica en Red en Enfermedades Infecciosas (CIBERINFEC), ISCIII, 28029 Madrid, Spain.ORCID 0000-0001-7611-781X
Joaquin DopazoBioinformatics Area, Andalusian Public Foundation Progress and Health-FPS, 41013 Sevilla, Spain.ORCID 0000-0003-3318-120X
Fundación Progreso y Salud · ESInstituto de Salud Carlos III · ESAndalusian Health Service · ESHospital Universitario Virgen del Rocío · ESConsejería de Salud y Consumo · ESInstituto de Biomedicina de Sevilla · ESInstituto de Filosofía · ESInstituto de Investigación Biosanitaria de Granada · ESPfizer-University of Granada-Junta de Andalucía Centre for Genomics and Oncological Research · ESUniversidad de Granada · ES
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
objectivesMore than two years into the COVID-19 pandemic, SARS-CoV-2 still remains a global public health problem. Successive waves of infection have produced new SARS-CoV-2 variants with new mutations for which the impact on COVID-19 severity and patient survival is uncertain.
methodsA total of 764 SARS-CoV-2 genomes, sequenced from COVID-19 patients, hospitalized from 19th February 2020 to 30 April 2021, along with their clinical data, were used for survival analysis.
resultsA significant association of B.1.1.7, the alpha lineage, with patient mortality (log hazard ratio (LHR) = 0.51, C.I. = [0.14,0.88]) was found upon adjustment by all the covariates known to affect COVID-19 prognosis. Moreover, survival analysis of mutations in the SARS-CoV-2 genome revealed 27 of them were significantly associated with higher mortality of patients. Most of these mutations were located in the genes coding for the S, ORF8, and N proteins.
conclusionsThis study illustrates how a combination of genomic and clinical data can provide solid evidence for the impact of viral lineage on patient survival.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Assessing the Impact of SARS-CoV-2 Lineages and Mutations on Patient Survival. · full record | OpenQuestion